Related Experiment Video

Updated: Jun 26, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Safety and Tolerability of Lete-cel in NSCLC-Letter

Di Zhao1,2, Jie Liu1,2

  • 1Jiangsu Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 1, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Experiment Videos

Last Updated: Jun 26, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

KRAS Q61 NSCLC: When Alleles Matter.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin-6: Analysis of the Phase 1/1b Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

A scoping review of applications of natural language processing for chronic pain research.

Discover artificial intelligence·2026

Study of deep learning cues for cross linguistic part of speech tagging in English- Malayalam code-mixed data.

Frontiers in big data·2026

Investigating lexical knowledge and lexical processing in order to explore their role in second language utterance fluency.

Cognitive processing·2026

Generative AI in medicine: use and acceptance among professionals in orthopedics and traumatology: a survey-based analysis in Germany.

Scientific reports·2026

Lesion-aware visio-linguistic context regularization for radiology report generation.

Medical image analysis·2026

DRE: An effective dual-refined method for integrating small and large language models in open-domain dialogue evaluation.

Neural networks : the official journal of the International Neural Network Society·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us